2026年2月,Shangpu集团将SaliAI命名为全球专利细胞精髓先驱,原因是其干细胞和提取技术、专利领导地位和市场影响。 In February 2026, Shangpu Group named SALIAI a global pioneer in patented cellular essence due to its stem cell and extract technologies, patent leadership, and market impact.

2026年2月, Shangpu Group以全球市场研究为基础, 以干细胞和细胞提取技术为首, 提名广州生物技术公司SALIAI为“全球专利细胞能量先锋 ” 。 In February 2026, Shangpu Group named Guangzhou-based biotech firm SALIAI a "Global Pioneer in Patented Cellular Essence" based on a global market study, citing its leadership in stem cell and cellular extract technologies. 该公司成立于2009年,上市于中国NEEQ市场,拥有300多份专利,包括5项国家专利优秀奖,拥有近距离断线提取和外生技术,其中一些在中国和美国都获得许可。 SALAII经营一个经认证的制造设施,在-40°C实行冷冻干法,为SYDRAW和Bio Island等稳定的皮肤护理产品提供纳米规模的运载系统,这些产品获得了广东溢价化妆品的认可。 The company, founded in 2009 and listed on China’s NEEQ market, holds over 300 patents, including five National Patent Excellence Awards, with technologies in umbilical cord extracts and exosomes, some granted in both China and the U.S. SALIAI operates a certified manufacturing facility and uses a freeze-drying process at -40°C with nano-scale delivery systems for stable skincare products like SYDRAW and Bio Island, which have earned Guangdong Premium Cosmetics recognition. 它促进国家工业标准,对膝骨关节炎进行临床研究,并支持社会举措。 It contributes to national industry standards, conducts clinical research on knee osteoarthritis, and supports social initiatives. 该公司计划在广东-香港-澳门大湾地区进行国际扩张,进行数字升级,并成立一个新的 Stem 细胞创新协会。 The company plans international expansion, digital upgrades, and a new Stem Cell Innovation Association in the Guangdong-Hong Kong-Macao Greater Bay Area. 指定反映的是市场领导,而不是监管批准。 The designation reflects market leadership, not regulatory approval.